DSM Capital Partners LLC Has $1.18 Million Position in Stryker Co. (NYSE:SYK)

DSM Capital Partners LLC grew its position in Stryker Co. (NYSE:SYK) by 358.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,289 shares of the medical technology company’s stock after purchasing an additional 2,572 shares during the period. DSM Capital Partners LLC’s holdings in Stryker were worth $1,184,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SYK. Dunhill Financial LLC raised its stake in Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares during the period. Darwin Wealth Management LLC acquired a new stake in shares of Stryker during the third quarter worth about $36,000. Activest Wealth Management bought a new position in shares of Stryker during the 4th quarter valued at about $36,000. Crews Bank & Trust bought a new position in shares of Stryker during the 4th quarter valued at about $39,000. Finally, Hara Capital LLC acquired a new position in shares of Stryker in the 3rd quarter valued at approximately $42,000. 77.09% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SYK has been the topic of a number of research reports. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research note on Tuesday. Barclays upped their target price on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Stifel Nicolaus lifted their price target on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Truist Financial upped their price objective on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Finally, Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $420.68.

Stryker Trading Up 0.1 %

Stryker stock opened at $385.44 on Wednesday. The stock has a 50-day simple moving average of $377.44 and a 200 day simple moving average of $367.94. The stock has a market capitalization of $147.08 billion, a P/E ratio of 49.67, a PEG ratio of 2.90 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the company posted $3.46 earnings per share. Analysts expect that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is presently 43.30%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.